Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Biologics : targets & therapy

Showing results (1-10 of 581) with videos related to

Pageof 59
Sort By:
Biologics : Targets & Therapy|October 13, 2022
Biosimilars: Science, Implications, and Potential Outlooks in the Middle East and AfricaRadwa Ahmed Batran, Mai Elmoshneb, Ahmed Salah Hussein, et al.
Biologics : Targets & Therapy|June 29, 2013
PEGylated interferon beta-1a in the treatment of multiple sclerosis - an updateReinhard Reuss
Biologics : Targets & Therapy|July 3, 2013
A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery diseaseJohan Bennett, Christophe Dubois
Biologics : Targets & Therapy|June 13, 2012
B cells contribute to MS pathogenesis through antibody-dependent and antibody-independent mechanismsHeather L Wilson
Biologics : Targets & Therapy|March 26, 2016
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinibJosephine Emole, Taiwo Talabi, Javier Pinilla-Ibarz
Biologics : Targets & Therapy|February 10, 2016
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patientsRoberto Guariglia, Maria Carmen Martorelli, Rosa Lerose, et al.
Biologics : Targets & Therapy|April 5, 2016
Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumabMaurizio Benucci, Francesca Meacci, Valentina Grossi, et al.
Biologics : Targets & Therapy|March 5, 2025
Unraveling Tumor-to-Tumor Metastasis: Insights into Pathogenesis, Diagnostic Challenges, and Treatment ModalitiesWennei Mei, Dongdong Zhang
Biologics : Targets & Therapy|November 18, 2024
Expression Levels of lncRNA NEAT1, miRNA-21, and IL-17 in a Group of Egyptian Patients with Behçet's Disease: Relation to Disease Manifestations and ActivityWafaa H Hussein, Hala Ramadan, Safa Labib, et al.
Biologics : Targets & Therapy|November 14, 2025
Beyond Monotherapy: Exploring the Efficacy and Safety of Dual Biologic Strategies in Rheumatic DiseasesFadi Hassan, Helana Jeries, Rula Daood, et al.
Pageof 59

Showing results (1-10 of 581) with videos related to

Sort By:
Pageof 59
Biologics : Targets & Therapy|October 13, 2022
Biosimilars: Science, Implications, and Potential Outlooks in the Middle East and AfricaRadwa Ahmed Batran, Mai Elmoshneb, Ahmed Salah Hussein, et al.
Biologics : Targets & Therapy|June 29, 2013
PEGylated interferon beta-1a in the treatment of multiple sclerosis - an updateReinhard Reuss
Biologics : Targets & Therapy|July 3, 2013
A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery diseaseJohan Bennett, Christophe Dubois
Biologics : Targets & Therapy|June 13, 2012
B cells contribute to MS pathogenesis through antibody-dependent and antibody-independent mechanismsHeather L Wilson
Biologics : Targets & Therapy|March 26, 2016
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinibJosephine Emole, Taiwo Talabi, Javier Pinilla-Ibarz
Biologics : Targets & Therapy|February 10, 2016
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patientsRoberto Guariglia, Maria Carmen Martorelli, Rosa Lerose, et al.
Biologics : Targets & Therapy|April 5, 2016
Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumabMaurizio Benucci, Francesca Meacci, Valentina Grossi, et al.
Biologics : Targets & Therapy|March 5, 2025
Unraveling Tumor-to-Tumor Metastasis: Insights into Pathogenesis, Diagnostic Challenges, and Treatment ModalitiesWennei Mei, Dongdong Zhang
Biologics : Targets & Therapy|November 18, 2024
Expression Levels of lncRNA NEAT1, miRNA-21, and IL-17 in a Group of Egyptian Patients with Behçet's Disease: Relation to Disease Manifestations and ActivityWafaa H Hussein, Hala Ramadan, Safa Labib, et al.
Biologics : Targets & Therapy|November 14, 2025
Beyond Monotherapy: Exploring the Efficacy and Safety of Dual Biologic Strategies in Rheumatic DiseasesFadi Hassan, Helana Jeries, Rula Daood, et al.
Pageof 59